COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01445587
Recruitment Status : Withdrawn (Based on the clinical activity, not safety data, of the AKT inhibitor, GSK has decided at this time to suspend further development of GSK2110183 as monotherapy.)
First Posted : October 4, 2011
Last Update Posted : March 26, 2012
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Actual Primary Completion Date : November 2011
Estimated Study Completion Date : November 2011